Aric Mathew Frantz

Title: Aric Mathew Frantz: Innovator in Lymphoma Prognostic Methods

Introduction

Aric Mathew Frantz is a notable inventor based in Hampton, Minnesota. He has made significant contributions to the field of medical diagnostics, particularly in lymphoma prognostic methods. His innovative approach has the potential to improve patient outcomes through more accurate differentiation of lymphoma types.

Latest Patents

Frantz holds a patent for "Lymphoma prognostic methods and kits." This patent describes a method for differentiating forms of lymphoma by analyzing a tumor tissue sample for the expression of specific markers, including CD28, ABCA5, CCDC3, and SMOC2. The CD28:ABCA5 expression ratio is utilized to distinguish T-cell tumors from B-cell tumors, while the CCDC3:SMOC2 expression ratio helps differentiate various T-cell tumors. This method can also include administering appropriate treatments based on the identified lymphoma type.

Career Highlights

Aric Mathew Frantz is affiliated with the Regents of the University of Minnesota, where he contributes to research and innovation in the medical field. His work is instrumental in advancing the understanding and treatment of lymphoma, showcasing his dedication to improving healthcare.

Collaborations

Frantz has collaborated with esteemed colleagues, including Jaime F. Modiano and Timothy David O'Brien. These partnerships enhance the research efforts and contribute to the development of effective lymphoma prognostic methods.

Conclusion

Aric Mathew Frantz is a pioneering inventor whose work in lymphoma prognostic methods is making a significant impact in the medical community. His innovative techniques hold promise for better diagnosis and treatment of lymphoma, ultimately benefiting patients and healthcare providers alike.